This result supports the data obtained by Zhao et al. who demonstrated that Verapamil, a specific inhibitor for MDR1 and MPR1 transporters, sensitizes PDA-resistant cells to gemcitabine by enhancing its accumulation [35] and strongly supports the role of BPTF as a therapeutic target. This evidence concerns the gene ABCB1 and Patent ductus arteriosus.